Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation
Background—In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and
systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation
to 2 predictions of time in therapeutic range (TTR). Methods and Results—The trial
randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for
at least 12 months. For each patient, a center average TTR was estimated with the use of a …
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and
systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation
to 2 predictions of time in therapeutic range (TTR). Methods and Results—The trial
randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for
at least 12 months. For each patient, a center average TTR was estimated with the use of a …
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillation
J Horowitz - 2013 - digital.library.adelaide.edu.au
BACKGROUND—In the Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced
stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects
in relation to 2 predictions of time in therapeutic range (TTR). METHODS AND RESULTS—
The trial randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or
warfarin for at least 12 months. For each patient, a center average TTR was estimated with …
Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced
stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects
in relation to 2 predictions of time in therapeutic range (TTR). METHODS AND RESULTS—
The trial randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or
warfarin for at least 12 months. For each patient, a center average TTR was estimated with …
以上显示的是最相近的搜索结果。 查看全部搜索结果